Solithromycin for the treatment of community-acquired bacterial pneumonia

Expert Review of Respiratory Medicine

Volumn 11, Issue 1, 2017, Pages 5-12

  Viasus, Diego ^a   Ramos, Oscar ^a   Ramos, Leidy ^a   Simonetti, Antonella F ^b   Carratalà, Jordi ^b,c  

^a UNIVERSIDAD DEL NORTE   (Colombia)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Community acquired pneumonia; efficacy; safety; solithromycin; trials

Indexed keywords

SOLITHROMYCIN; ANTIINFECTIVE AGENT; MACROLIDE; TRIAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN ALLERGY; URTICARIA; VOMITING; COMMUNITY-ACQUIRED INFECTIONS; PNEUMONIA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; TRIAZOLES;

EID: 84992697442     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2017.1249852     Document Type: Article

References (49)

1. File TM, Jr, Marrie TJ., Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–141.
2. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014;370(6):543–551.
3. Schnoor M, Hedicke J, Dalhoff K, et al. CAPNETZ study group approaches to estimate the population-based incidence of community acquired pneumonia. J Infect. 2007;55(3):233–239.
4. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275:134–141.
5. Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis. 2001;33:158–165.
6. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. Crit Care Clin. 2013;29(3):563–601.
7. Mandell LA. Community-acquired pneumonia:an overview. Postgrad Med. 2015;127(6):607–615.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America; American thoracic society. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
9. Viasus D, Garcia-Vidal C, Carratalà J. Advances in antibiotic therapy for community-acquired pneumonia. Curr Opin Pulm Med. 2013;19(3):209–215.
10. Woodhead M, Blasi F, Ewig S, et al. Joint taskforce of the European respiratory society and European society for clinical microbiology and infectious diseases. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17(Suppl 6):E1–E59.
11. File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm. 2009;15(Suppl 2):S5–S11.
12. Maselli DJ, Fernandez JF, Whong CY, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist. 2012;5:43–51.
13. Garcia-Vidal C, Carratalà J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med. 2009;30(2):154–160.
14. Jones RN, Sader HS, Moet GJ, et al. Declining antimicrobial susceptibility of streptococcus pneumoniae in the United States:report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2010;68:334–336.
15. Antimicrobial resistance surveillance in Europe 2014. European Antimicrobial Resistance Surveillance Network (EARS-Net). [cited 2015 June]. Available from:http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf
16. Chen HH, Li HC, Su LH, et al. Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era. J Microbiol Immunol Infect. 2016;pii:S1684-1182(16)30044-5. DOI:10.1016/j.jmii.2016.05.003
17. Pfaller MA, Farrell DJ, Sader HS, et al. AWARE ceftaroline surveillance program (2008-2010):trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55(Suppl 3):S187–S193.
18. Morrissey I, Maher K, Williams L, et al. BSAC working parties on resistance surveillance. Nonsusceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland 1999-2007. J Antimicrob Chemother. 2008;62(Suppl2):ii97–ii103.
19. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae:characteristics of isolates and clinical aspects of community acquired pneumonia. J Infect Chemother. 2010;16:78–86.
20. Bebear CM, Pereyre S, Peuchant O. Mycoplasma pneumoniae:susceptibility and resistance to antibiotics. Future Microbiol. 2011;6:423–431.
21. Spuesens EB, Meijer A, Bierschenk D, et al. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands. J Clin Microbiol. 2012;50:1999–2004.
22. Gullsby K, Bondeson K. No detection of macrolide-resistant Mycoplasma pneumoniae from Swedish patients, 1996-2013. Infect Ecol Epidemiol. 2016;6:31374.
23. Georgopapadakou NH. The wobbly status of ketolides:where do we stand? Expert Opin Investig Drugs. 2014;23(10):1313–1319.
24. Llano-Sotelo B, Dunkle J, Klepacki D, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010;54(12):4961–4970.
25. Rodgers W[, Frazier AD, Champney WS. Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob Agents Chemother. 2013;57(4):1632–1637.
26. Farrell DJ, Flamm RK, Sader HS, et al. Results from the solithromycin international surveillance program (2014). Antimicrob Agents Chemother. 2016;60(6):3662–3668.
27. Farrell DJ, Sader HS, Castanheira M, et al. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents. 2010;35(6):537–543.
28. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother. 2009;53(5):2139–2141.
29. Mallegol J, Fernandes P, Melano RG, et al. Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1. Antimicrob Agents Chemother. 2014;58(2):909–915.
30. Bruin JP, Diederen BM, Ijzerman EP, et al. Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates. Diagn Microbiol Infect Dis. 2013;76:339–342.
31. Putnam SD, Sader HS, Farrell DJ, et al. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide:activity against staphylococci and enterococci. Int J Antimicrob Agents. 2011;37(1):39–45.
32. Fernandes P, Martens E, Bertrand D, et al. The solithromycin journey-It is all in the chemistry. Bioorg Med Chem. 2016; pii:S0968-0896(16)30642-3. [Epub ahead of print].
33. Still JG, Schranz J, Degenhardt TP, et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother. 2011;55(5):1997–2003.
34. Schranz J, Clark K, Marion A, et al. [cited 2016 June]. Available from:http://www.cempra.com/common/pdf/abstracts/ECCMID%202011_Schranz_Solithromycin%20Phase%20I%20IV_Abstract%20095.pdf
35. Rodvold KA, Gotfried MH, Still JG, et al. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012;56(10):5076–5081.• Excellent study outlining the concentrations of solithromycin in epithelial lining fluid and alveolar macrophages.
36. Jamieson BD, Ciric S, Fernandes P. Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrob Agents Chemother. 2015;59(8):4379–4386.
37. Keelan JA, Pugazhenthi K. Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta. Placenta. 2014;35(12):1043–1048.
38. Keelan JA, Kemp MW, Payne MS, et al. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrob Agents Chemother. 2014;58(1):447–454.
39. Van Bambeke F, Tulkens PM. The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Rev Anti Infect Ther. 2016;14(3):311–324.
40. Andes DR, Okusanya OO, Forrest A, et al. Pharmacokinetic-pharmacodynamic analysis of solithromycin against Streptococcus pneumoniae using data from a murine-lunginfection model. [cited 2016 Sep. Available from:http://www.cempra.com/common/pdf/Posters/00190_CEM_101_pkpd_sp_murine_ICAC10_A1_688_08sep10.pdf
41. Okusanya OO, Bhavnani SM, Forrest A, et al. Pharmacokinetic-pharmacodynamic target attainment analysis supporting solithromycin (CEM-101) phase 2 dose selection. [cited 2016 Sep]. Available from:http://www.cempra.com/common/pdf/Posters/00182_CEM_101_PKPD_TA_ICAAC10_A1_692_08sep10.pdf
42. Okusanya OO, Bhavnani SM, Forrest A, et al. Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analysis for solithromycin to support intravenous dose selection in patients with community-acquired bacterial pneumonia. [cited 2016 Sep]. Available from:http://www.cempra.com/common/pdf/posters/ICAAC%202012_A1269_Bhavnani_Soli 20PPK%20and%20PKPD%20TA.PDF
43. Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013;345(1):76–84.
44. Ciric S, Dunnington K, Gartner MR, et al. Assessment of a pharmacokinetic drug interaction between solithromycin and digoxin. cited 2016 June]. Available at:http://www.cempra.com/common/pdf/abstracts/Ciric%20AAPS%202015%20Abstract.pdf
45. Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57(6):2526–2534.• First trial to suggest the efficacy of solithromycin therapy in patients with CABP.
46. Barrera CM, Mykietiuk A, Metev H, et al.; SOLITAIRE-ORAL Pneumonia Team. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia:a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016; 16(4):421–430.• Large randomized control trial demonstrating the clinical efficacy of oral solithromycin in the management of patients with CABP.
47. File TM, Jr, Rewerska B, Vucinić-Mihailović V, et al.; SOLITAIRE-IV Pneumonia Team. SOLITAIRE-IV:a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016;63(8):1007–1016.• Large randomized control trial demonstrating the clinical efficacy of intravenous solithromycin in the management of patients with CABP.
48. Liapikou A, Torres A. Current treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2013;14(10):1319–1332.
49. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections:analysis of two prospective cohort studies. BMJ. 2013;346:f1235.